The Vanishing Stent

How a Disappearing Heart Implant Could Revolutionize Cardiac Care

Article Navigation

The Permanent Problem

Imagine a cast that never comes off a healed bone. That's essentially the dilemma with traditional metal stents—they remain permanently in arteries after restoring blood flow to the heart.

While lifesaving initially, these metallic cages can cause long-term complications: chronic inflammation, restricted vessel movement, and lifelong dependency on blood thinners 2 . Enter bioresorbable vascular scaffolds (BRS)—stents designed to vanish after doing their job. But early versions failed catastrophically, with some showing alarming thrombosis rates 2 5 . This is the story of a breakthrough polymer that might finally deliver on the promise of truly "temporary" stents.

Key Issue

Traditional metal stents remain permanently, potentially causing long-term complications like chronic inflammation and restricted vessel movement.

Core Concepts: The Science of Disappearing Acts

Polymer Evolution: From Rigid to Resilient

Traditional BRS used crystalline poly-L-lactic acid (PLLA)—stiff but brittle. The novel scaffold employs ultrahigh molecular weight amorphous PLLA:

  • Flexibility: Amorphous structure allows 150–200% elongation versus 2–10% in crystalline PLLA 6
  • Strength: Higher tensile strength (100–110 MPa) resists artery recoil 6
  • Stealth Degradation: Loses molecular weight gradually (50% at 8 months, 75% at 12 months) without sudden structural collapse 3
Why Pigs? The Gold Standard Model

Porcine coronary arteries mirror human vascular biology in critical ways:

  • Similar artery size (2.5–4.0 mm diameter)
  • Comparable healing response (neointima formation)
  • Predictive of clinical outcomes 1
Pig coronary model

The Landmark Experiment: A Four-Year Odyssey

The Scaffold: FORTITUDE®

Developed by Amaranth Medical, this non-drug-eluting BRS had:

  • 150-μm struts (thinner than first-gen Absorb BVS' 156 μm)
  • Platinum markers for tracking under X-ray
  • Radial force comparable to bare metal stents 3 4
Scaffold Properties
Feature FORTITUDE® BRS Traditional BMS
Material Amorphous PLLA Cobalt-chromium
Strut Thickness 150 μm 96 μm
Degradation Time ~4 years Permanent
Drug Coating None (study) None
Methodology: Precision Tracking

Step 1: Implantation

  • 16 Yucatan minipigs received BRS or BMS in coronary arteries
  • Overstretch ratio strictly controlled to 1:1.1 3 4

Step 2: The OCT Magic

Optical Coherence Tomography acted like a microscopic time-lapse camera:

  • Strut-Level Resolution: Detected malapposition >105 μm (strut thickness)
  • 3D Reconstruction: Tracked lumen/scaffold areas yearly
  • No shadowing behind polymer struts (unlike metal) 5
Results: The Four-Year Transformation
Year 1

Scaffold intact, 97% strut coverage

Year 2

Molecular weight dropped 50%, radial force stable

Year 3

Scaffold area enlargement begins

Year 4

Lumen area 71% larger vs. BMS (13.19 ± 1.50 mm² vs. 7.69 ± 2.41 mm²; p<0.01) 3 4

OCT Metrics Over Time
Time Point Lumen Area (mm²) Scaffold Area (mm²) Neointimal Thickness (mm)
28 days 6.81 ± 0.92 7.95 ± 1.10 0.10 ± 0.03
1 year 7.20 ± 1.15 8.30 ± 1.25 0.18 ± 0.06
4 years 13.19 ± 1.50 15.62 ± 1.95 0.22 ± 0.05
Analysis: Why This Matters
  • Expansive Remodeling: Arteries widened as the scaffold dissolved—a phenomenon never seen with metal stents.
  • Clean Biocompatibility: Inflammation scores matched BMS (0.6–0.8 on 4-point scale), confirming no polymer toxicity 4 8 .
Artery expansion

The Scientist's Toolkit: Key Research Assets

Essential Research Reagents & Tools
Item Function Experimental Role
Yucatan Minipigs Human-like coronary anatomy In vivo implantation model
FD-OCT System High-resolution intravascular imaging Tracked strut apposition/coverage
Polymer Gel Chromatography Measures molecular weight loss Quantified degradation rate
J-Crimpâ„¢ Radial Tester Mechanical strength assessment Confirmed radial force retention
Histomorphometry Cellular-level analysis Scored inflammation/endothelialization
Oat1/3-IN-1C16H12O6
Xylose-d1-2C5H10O5
Ramipril-d3C23H32N2O5
Cox-2-IN-33C20H13ClF3N5O4
NNRTIs-IN-1C28H22N6O3

The Future: Where Do We Go From Here?

Next-Gen Upgrades
  • Albumin Stealth Coating: PDA-BSA surface modification reduces platelet adhesion by 90% 8
  • Iron-Based BRS: Corrodes completely by 5 years with late lumen enlargement
  • Thinner Struts: 100-μm designs to improve hemodynamics 6
Remaining Challenges
  • Calcium Compatibility: Performance in heavily calcified arteries?
  • Drug-Eluting Versions: Balancing sirolimus delivery with polymer integrity 5
Future challenges

Conclusion: A Paradigm Shift in Progress

"Those that fail to learn from history are doomed to repeat it" 2 .

Winston Churchill

The FORTITUDE® scaffold represents a hard-won lesson in polymer science: amorphous PLLA's unique combination of strength, flexibility, and clean degradation could finally make the "vanishing stent" dream a clinical reality. While human trials are pending, the four-year porcine data offers something revolutionary: proof that our arteries can heal better when we give them back their freedom.

References